LENSAR logo
LENSAR LNSR
$ 5.25 -1.87%
report update icon

Quarterly report 2026-Q1
added 05-08-2026

LENSAR Income Statement 2025-2011 | LNSR

Brief overview of income trends at LENSAR

This overview is based on financial performance over the past five years. LENSAR reported revenue of 26.4 million dollars in 2020 and 58.4 million dollars by 2025. The total change was +121.5%, with a CAGR of approximately 17.2%. Revenue followed a strong upward trend without signs of stagnation.

The gross result shifted from 14.1 million dollars to 27.1 million dollars, or +92.7%. The relationship between sales and direct costs deteriorated. Gross profit as a share of revenue changed from 53.4% to 46.4%. Weakening gross profitability reduces the quality of the top-line trend.

EBITDA changed from −17.2 million dollars to −21 million dollars (−21.7%). Operating performance weakened relative to revenue. EBITDA margin moved from −65.4% to −35.9%. Higher profitability strengthens the quality of operating growth.

Net income moved from −$19.8 million at the start to −$34.3 million at the end. Larger losses indicate rising pressure on the business.

Market capitalization changed from $32.3 million to $71.3 million (+120.6%). Market optimism is not supported by the direction of the results.

Overall conclusion

The results contain several connected negative signals. The strongest signals are an improving EBITDA margin and a larger revenue base. The weaker side of the profile includes limited operating profitability, lower net income and pressure from direct costs. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement LENSAR

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

71.3 M 130 M 54.3 M 32.9 M 56.2 M 32.3 M - - - - - - - - -

Shares

12 M 11.5 M 11 M 10.2 M 9.37 M 4.62 M - - - - - - - - -

Historical Prices

5.96 11.3 4.95 3.24 5.99 7.25 - - - - - - - - -

Net Income

-34.3 M -31.4 M -14.4 M -19.9 M -19.6 M -19.8 M -14.7 M - - - - - - - -

Revenue

58.4 M 53.5 M 42.2 M 35.4 M 34.5 M 26.4 M 30.5 M - - - - - - - -

Cost of Revenue

31.3 M 27.6 M 21.1 M 15.4 M 16.6 M 12.3 M 17.3 M - - - - - - - -

Gross Profit

- - - - - 14.1 M 13.2 M - - - - - - - -

Operating Income

-24.6 M -10.7 M -12.2 M -20.2 M -19.7 M -18.5 M -12.7 M - - - - - - - -

Interest Expense

636 K 660 K 698 K 263 K 51 K 1.34 M 2 M - - - - - - - -

EBITDA

-21 M -7.7 M -9.81 M -17.9 M -18.1 M -17.2 M -11.5 M - - - - - - - -

Operating Expenses

- - - - - 32.6 M 25.9 M - - - - - - - -

General and Administrative Expenses

45.2 M 26.5 M 26.1 M 27.2 M 23.9 M 23.8 M - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement LENSAR

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

12.2 M 12 M 11.9 M 11.8 M 11.7 M 11.6 M 11.5 M 11.4 M 11.3 M 11.1 M 10.8 M 10.7 M 11.1 M 10.2 M 10.1 M 9.97 M 11 M 9.44 M 9.3 M 9.19 M 10.9 M 7.46 M 1.07 M 1.07 M 1.07 M 1.07 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

36.3 M -3.71 M -1.76 M -27.3 M - -1.5 M -9.04 M -2.16 M - 2.57 M -8.75 M -4.27 M - -3.99 M -6.76 M -6.67 M - -6.16 M -4.36 M -5.18 M - -4.76 M -4.5 M -3.69 M - -5.82 M -3.79 M -2.58 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

13.4 M 14.3 M 13.9 M 14.2 M - 13.5 M 12.6 M 10.6 M - 9.8 M 12 M 8.25 M - 7.75 M 8.04 M 9.34 M - 8.27 M 7.92 M 7.04 M - 7.14 M 5.05 M 5.91 M - 8.07 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

7.05 M 8.28 M 6.91 M 7.03 M - 7.27 M 5.82 M 4.92 M - 4.92 M 5.25 M 3.93 M - 3.86 M 3.15 M 4.65 M - 4.42 M 3.46 M 3.15 M - 3.25 M 3.1 M 2.34 M - 4.79 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

2.24 M -7.58 M -6.29 M -5.79 M - -1.24 M -5.28 M -2.85 M - -2.04 M -2.87 M -4.36 M - -4.08 M -6.8 M -6.68 M - -6.16 M -4.38 M -5.2 M - -4.71 M -3.84 M -3.1 M - -5.34 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

145 K 133 K 193 K 159 K - 153 K 160 K 198 K - 265 K 111 K 89 K - 92 K 39 K 9 K - 10 K 13 K 18 K - 65 K 671 K 604 K - 494 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

3.14 M -7.35 M -6.06 M -4.95 M - -1.01 M -5.05 M -2.2 M - -1.77 M -2.59 M -3.78 M - -3.81 M -6.51 M -6.14 M - -5.1 M -3.7 M -4.87 M - -3.68 M -3.04 M -2.62 M - -3.25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

2.53 M 12 M 11.7 M 11.1 M - 6.08 M 6.78 M 6.8 M - 5.12 M 7.85 M 6.76 M - 6.12 M 7.57 M 6.28 M - 6.52 M 5.52 M 6.04 M - 6.29 M 4.04 M 4.78 M - 3.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company LENSAR (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Myomo Myomo
MYO
$ 0.93 -3.11 % $ 38.9 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.24 -0.14 % $ 219 M canadaCanada
AxoGen AxoGen
AXGN
$ 41.37 0.53 % $ 1.91 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.38 -3.15 % $ 144 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.44 -3.69 % $ 124 M australiaAustralia
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.74 -1.86 % $ 9.37 B usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.66 0.31 % $ 28.3 B britainBritain
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.4 -1.23 % $ 627 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 18.59 4.67 % $ 1.26 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.14 -2.68 % $ 400 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 -1.95 % $ 14.6 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.65 -2.27 % $ 453 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.95 -1.62 % $ 453 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 -4.32 % $ 21.8 M usaUSA
Beyond Air Beyond Air
XAIR
$ 5.51 0.92 % $ 45.7 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 0.14 % $ 60 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 97.15 1.46 % $ 19.2 B usaUSA